Cinacalcet hydrochloride (Amgen).
Amgen Inc and Kirin Brewery Co Ltd, under license from NPS Pharmaceuticals Inc, are developing cinacalcet hydrochloride, the lead compound in a series of calcimimetics, for the potential treatment of primary and secondary hyperparathyroidism. Tecalcet hydrochloride was the first compound from this class to be extensively studied and most of the pharmacological data disclosed is for this compound. Cinacalcet hydrochloride was developed in an effort to improve on the poor pharmacokinetics and metabolism of tecalcet hydrochloride.
Iqbal
Jameel
J
Mount Sinai Bone Program, Division of Endocrinology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Zaidi
Mone
M
Schneider
Adina E
AE
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D000069449:Cinacalcet; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy*; D009281:Naphthalenes / Q000737:chemistry / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D016896:Treatment Outcome
D009281:Naphthalenes; D002118:Calcium; D000069449:Cinacalcet